Community Bank & Trust Waco Texas Has $1.61 Million Stock Position in Pfizer Inc. $PFE

Community Bank & Trust Waco Texas decreased its position in Pfizer Inc. (NYSE:PFE) by 1.1% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 66,429 shares of the biopharmaceutical company’s stock after selling 719 shares during the period. Community Bank & Trust Waco Texas’ holdings in Pfizer were worth $1,610,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in PFE. Brighton Jones LLC grew its holdings in shares of Pfizer by 1,282.4% in the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock valued at $17,677,000 after buying an additional 618,117 shares during the period. Revolve Wealth Partners LLC boosted its stake in Pfizer by 12.5% in the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock worth $498,000 after purchasing an additional 2,087 shares during the period. GAMMA Investing LLC boosted its stake in Pfizer by 4,183.6% in the 1st quarter. GAMMA Investing LLC now owns 1,599,742 shares of the biopharmaceutical company’s stock worth $40,537,000 after purchasing an additional 1,562,396 shares during the period. NBC Securities Inc. boosted its stake in Pfizer by 100,468.5% in the 1st quarter. NBC Securities Inc. now owns 54,307 shares of the biopharmaceutical company’s stock worth $1,376,000 after purchasing an additional 54,253 shares during the period. Finally, Merit Financial Group LLC boosted its stake in Pfizer by 24.1% in the 1st quarter. Merit Financial Group LLC now owns 158,871 shares of the biopharmaceutical company’s stock worth $4,026,000 after purchasing an additional 30,904 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Up 6.8%

Shares of PFE stock opened at $25.46 on Wednesday. The stock has a market cap of $144.75 billion, a price-to-earnings ratio of 13.54, a PEG ratio of 0.77 and a beta of 0.55. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $30.43. The firm’s 50-day moving average is $24.55 and its 200-day moving average is $24.11.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. The firm had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business’s revenue was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Sell-side analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages recently weighed in on PFE. Wall Street Zen lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday. Morgan Stanley upped their target price on shares of Pfizer from $32.00 to $33.00 and gave the stock an “equal weight” rating in a research note on Wednesday, August 6th. Citigroup upped their target price on shares of Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 6th. Finally, Bank of America boosted their price target on shares of Pfizer from $27.00 to $28.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $28.12.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.